You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

934 Results
Document
Aug 2023
Document
Aug 2023
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Statistical Reports
Jan 2024
Document
Nov 2023
Guidelines and Advice
Status: Current
ID: GL-END 3-25
Nov 2023
Document
Nov 2023
Document
Nov 2023
Document
Dec 2023

Pages